ArticleInternational journal of women's health2026
Synchronous Ovarian and Cervical Malignancies: A Case Report of Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and Niraparib Maintenance.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The coexistence of ovarian carcinosarcoma, contralateral high-grade serous ovarian carcinoma, and synchronous cervical squamous cell carcinoma as multiple primary gynecologic malignancies is exceedingly rare. The tumor biology of such synchronous multiple primary malignancies (MPMNs), including pathogenesis, disease progression and prognostic impact, is not well established. Patients and Methods: Here we report the case of a 66-year-old woman diagnosed with distinct tumors: left ovarian carcinosarcoma, right ovarian high-grade serous carcinoma, and cervical squamous cell carcinoma, and review the literature on multiple primary malignancies (MPMNs). Results: Following preoperative neoadjuvant chemotherapy with three cycles of paclitaxel plus carboplatin, the patient achieved a significant reduction in tumor volume and underwent interval cytoreductive surgery. After that, she received five cycles of adjuvant chemotherapy: two cycles of paclitaxel plus carboplatin (with bevacizumab added in the second cycle), followed by three cycles of paclitaxel plus cisplatin. Despite testing negative for HRD and BRCA mutations, she subsequently received maintenance therapy with niraparib. This treatment led to a progression-free survival of nearly one year. Although her ovarian cancer later recurred, her overall survival exceeded three years. Conclusion: Multiple primary malignant neoplasms (MPMNs) are rare and there are no unified clinical guideline for this situation. This report is valuable for enhancing clinical recognition of this rare condition and contributes to optimizing and personalizing MPMNs care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.